We assessed the expression of miR-17, miR-106a, miR-106b, miR-18a, and miR-19a in AIDS-NHL subtypes, BL (n = 5), DLBCL (n = 8), PCNSL (n = 5), PEL (n = 5) and compared it to control CD19+ B cells isolated from PBMC and tonsils (Figure 2 A–E). This evidence concerns the gene CD19 and primary effusion lymphoma.